Tower Research Capital LLC TRC Purchases 4,983 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Tower Research Capital LLC TRC increased its position in Design Therapeutics, Inc. (NASDAQ:DSGN) by 30.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,503 shares of the company’s stock after acquiring an additional 4,983 shares during the period. Tower Research Capital LLC TRC’s holdings in Design Therapeutics were worth $57,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in shares of Design Therapeutics by 38,433.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company’s stock valued at $31,000 after purchasing an additional 11,530 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Design Therapeutics by 317.6% in the fourth quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock valued at $32,000 after buying an additional 9,126 shares during the period. SG Americas Securities LLC bought a new position in Design Therapeutics in the third quarter valued at approximately $47,000. Corton Capital Inc. boosted its stake in Design Therapeutics by 56.6% in the third quarter. Corton Capital Inc. now owns 27,134 shares of the company’s stock valued at $64,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Algert Global LLC grew its holdings in Design Therapeutics by 83.3% during the 3rd quarter. Algert Global LLC now owns 35,620 shares of the company’s stock worth $84,000 after acquiring an additional 16,190 shares during the period. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Price Performance

Shares of NASDAQ DSGN traded down $0.06 during midday trading on Monday, reaching $3.72. 164,996 shares of the stock were exchanged, compared to its average volume of 258,934. Design Therapeutics, Inc. has a 12 month low of $1.94 and a 12 month high of $8.47. The company has a market capitalization of $210.14 million, a price-to-earnings ratio of -3.10 and a beta of 1.82. The business has a 50-day simple moving average of $3.32 and a two-hundred day simple moving average of $2.69.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Tuesday, March 19th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.11. Equities research analysts expect that Design Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.

Insider Activity

In other Design Therapeutics news, Director John P. Schmid bought 17,809 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average cost of $3.74 per share, with a total value of $66,605.66. Following the purchase, the director now owns 26,965 shares in the company, valued at $100,849.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director John P. Schmid bought 17,809 shares of the stock in a transaction on Monday, March 25th. The stock was purchased at an average price of $3.74 per share, for a total transaction of $66,605.66. Following the acquisition, the director now owns 26,965 shares in the company, valued at $100,849.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John P. Schmid purchased 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the purchase, the director now directly owns 9,156 shares in the company, valued at $33,144.72. The disclosure for this purchase can be found here. 25.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DSGN. Wedbush reissued a “neutral” rating and issued a $5.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a research note on Wednesday, March 20th. Seven research analysts have rated the stock with a hold rating, According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.